Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990627 | 1.00 | MAP4K1 (0.35) | MAP4K1HTR2CSLC6A4HTR2ARPS6KA2 | |
| SCHEMBL30913157 | 1.00 | MAP4K1 (0.35) | MAP4K1HTR2CSLC6A4HTR2ARPS6KA2 | |
| SCHEMBL30913160 | 0.88 | PIK3C3 (0.41) | — | |
| SCHEMBL30227816 | 0.85 | MAP4K1 (0.35) | MAP4K1 | |
| SCHEMBL30913142 | 0.84 | CACNA1G (0.34) | HTR2CSLC6A4HTR2A | |
| SCHEMBL28975036 | 0.83 | MAP4K1 (0.38) | MAP4K1RPS6KA2PRKD2 | |
| SCHEMBL29261261 | 0.83 | MAP4K1 (0.38) | MAP4K1RPS6KA2PRKD2 | |
| SCHEMBL30913139 | 0.82 | AURKA (0.37) | HTR2CSLC6A4 | |
| SCHEMBL30913137 | 0.81 | MAP4K1 (0.34) | MAP4K1HTR2CSLC6A4 | |
| SCHEMBL25100255 | 0.80 | MAP4K1 (0.42) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2020100027-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2020-05-22 | — | — | WO | disclosed |